Special Article
Artificial intelligence software in biomedical imaging: a pharmaceutical perspective on radiology and contrast-enhanced ultrasound applications
G. Valbusa1, A. Fringuello Mingo2, S. Colombo Serra3
- Bracco Imaging SpA, Milano, Italy. giovanni.valbusa@bracco.com
- Bracco Imaging SpA, Milano, Italy.
- Bracco Imaging SpA, Milano, Italy.
CER18695
2025 Vol.43, N°5
PI 0822, PF 0828
Special Article
Free to view
(click on article PDF icon to read the article)
PMID: 40338060 [PubMed]
Received: 07/03/2025
Accepted : 24/04/2025
In Press: 08/05/2025
Published: 08/05/2025
Abstract
Artificial intelligence (AI) is rapidly transforming radiology, with over 200 CE-marked products in the EU and more than 750 AI-based devices authorised by the FDA in the US, mainly used for x-ray, CT, MRI, and ultrasound imaging. Despite regulatory challenges, the adoption of AI in radiology is growing, driven by venture capital funding and anticipated cost and efficiency benefits. Clinical and economic barriers, inconsistent performance, integration challenges, and lack of reimbursement are currently hindering the widespread adoption of AI. However, the role of AI in the future of medical imaging is generally expected to be significant. Contrast agents are crucial in imaging for improving sensitivity and specificity, widely used in angiography, cardiology, and oncology. AI can optimise the use of these agents, reducing dosages and improving image quality. Moreover, AI’s synergy with contrast agents in enhancing image clarity and supporting diagnostic accuracy holds significant potential for advancing clinical practices. In summary, the integration of AI with contrast media in radiology offers promising improvements in image quality, diagnostic accuracy, and operational efficiency, although clinical and regulatory hurdles must be addressed for broader application.
